Clover Biopharmaceuticals, Ltd. (HKEX: 02197) announced on September 6 positive preliminary Phase 2 data from a trial in Australia testing two combination vaccine candidates, SCB-1022 (targeting RSV and hMPV) and SCB-1033 (targeting RSV, hMPV, and PIV3), in adults ages 60 to 85. The results are notable partly because two of the three viruses involved, human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3), currently have no licensed vaccine anywhere in the world, unlike RSV, which already has three approved vaccines on the market.

Trial Design

The trial is a randomized, observer-blinded, multicenter study of 420 older adults, split between SCB-1022, SCB-1033, and placebo. Both candidates use Clover’s Trimer-Tag technology, a protein-based vaccine platform built around prefusion-stabilized versions of each virus’s F protein, a design approach conceptually similar to how existing approved RSV vaccines work, but extended here to cover additional respiratory viruses in one shot.

What the Antibody Data Showed

On immunogenicity, measured 28 days after vaccination, Clover reported neutralizing antibody increases of roughly 6 to 9 times baseline for RSV and roughly 6 to 8 times baseline for hMPV. The PIV3 response was smaller, a bit more than 3 times baseline overall, which the company attributes to a biological quirk: most people already carry antibodies against a different part of the PIV3 virus, so there is less room for a vaccine targeting the prefusion F protein specifically to multiply that particular antibody pool, even though the antibodies it does generate are described as highly potent, with increases up to roughly 20-fold in that specific antibody type. Two other findings stood out: older participants in their late 70s and 80s showed no drop-off in response compared with those in their 60s and early 70s, and adding the PIV3 component in SCB-1033 did not appear to weaken the RSV or hMPV responses compared with the two-virus SCB-1022 candidate.

The Infection-Rate Claim Comes With a Caveat

On a secondary measure, Clover reported a roughly 62% lower rate of any respiratory tract infection in the combined vaccine groups compared with placebo during the 28 days after vaccination. This figure comes with an important caveat that Clover discloses directly: it is based on adverse-event reporting alone, without any lab testing to confirm which specific virus caused each infection. That makes it a much weaker form of evidence than a confirmed-infection efficacy result, and it should be read as a supportive signal rather than proof the vaccines prevented RSV, hMPV, or PIV3 infections specifically. The trial period did coincide with a documented RSV outbreak alongside hMPV and PIV circulation in Australia, based on data Clover cites from Australian government health surveillance sources, which is relevant context for interpreting the infection-rate comparison but does not substitute for confirmed-case data.

Safety and Manufacturing

On safety, Clover says both candidates were generally well tolerated, with the most common side effects, fatigue, headache, and injection site pain, lasting about two days on average and occurring at similar rates to placebo for unsolicited adverse events. The company reported no vaccine-related serious adverse events, no adverse events of special interest, and no discontinuations due to side effects.

Separately, Clover says it successfully scaled up production of the vaccines’ antigen components using a 2,000-liter bioreactor process, running in parallel with the clinical trial. Demonstrating that a vaccine candidate can be manufactured at that commercial scale, rather than only in small clinical-trial batches, is a meaningful practical step toward eventual commercialization, independent of the trial’s efficacy results.

What the Company Is Saying

Clover CEO Joshua Liang said the results support a potential first-in-class and best-in-class profile for the combination candidates, and specifically highlighted a possible use case of re-vaccinating people who already received one of the approved single-target RSV vaccines, to broaden their protection to include hMPV and PIV3 as well. That specific differentiation claim is the company’s own framing rather than something demonstrated head-to-head against an approved RSV vaccine in this trial.

The Competitive Landscape

Clover is not the only company working on hMPV and PIV3 vaccines: Moderna has an mRNA-based hMPV/PIV3 combination candidate, mRNA-1653, in earlier-stage trials, and Sanofi has a protein-based hMPV/RSV bivalent candidate, SP0340, that has received FDA Fast Track designation and is in Phase 1. None of these programs, including Clover’s, has yet produced late-stage efficacy data confirming protection against confirmed infections in a large trial.

What’s Next

Clover says it will now evaluate mid- and late-stage development plans, along with potential global collaboration opportunities, though no specific next trial, timeline, or partnership was announced. This article covers a preliminary Phase 2 clinical trial disclosure and is not medical or investment advice.

Sources

Clover Biopharma: Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults, PRNewswire, September 6, 2026.

PMC (National Library of Medicine): Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment, cited for background confirming no licensed hMPV or PIV3 vaccine currently exists and on competing vaccine candidates.

Editorial Disclosure

This article is based on a press release issued by Clover Biopharma on September 6, 2026, distributed via PRNewswire, with background on the competitive and regulatory landscape for hMPV and PIV3 vaccines drawn from independent scientific literature cited above. Clover Biopharmaceuticals trades on the Hong Kong Stock Exchange under the ticker 02197. BioTech Stocks Daily was not compensated for this coverage. The reported reduction in respiratory tract infection rates is based on adverse-event reporting without laboratory confirmation of infection cause, a meaningfully weaker form of evidence than a confirmed-case efficacy result; statements regarding the vaccines’ potential best-in-class profile are the company’s own characterizations. This article is for informational and educational purposes only, does not constitute investment advice, and is not medical advice. Consult a qualified healthcare professional for medical guidance. See our full DISCLAIMER.